Therapeutic potential of PMEA as an antiviral drug

Reviews in Medical Virology

Volumn 4, Issue 3, 1994, Pages 147-159

  Naesens, L ^a   Balzarini, J ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ADEFOVIR; ANTIVIRUS AGENT; NUCLEOSIDE ANALOG;

ANTIVIRAL ACTIVITY; DNA VIRUS; NONHUMAN; REVIEW;

EID: 0028560018     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1980040302     Document Type: Article

References (78)

1. A novel selective broad‐spectrum anti‐DNA virus agent
2. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
3. Broad spectrum anti‐DNA virus and anti‐retrovirus activity of phosphonylmethoxy‐alkylpurines and ‐pyramidines
4. Synthesis and biological activities of phosphonylalkylpurine derivatives
5. Acyclic purine nucleoside phosphonates as retrovirus inhibitors
6. Particular characteristics of the anti‐human cytomegalovirus activity of ( S)‐1‐(3‐hydroxy‐2‐phoshonylmethoxypropyl)cyt9sine (HPMPC) in vitro
7. (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication
8. Therapeutic potential of HPMPC as an antiviral drug
9. 9 ‐ [(. RS) ‐ 3 ‐ Fluoro ‐ 2 ‐ phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vivo and in vivo
10. Differential antiherpesvirus and antiretrovirus effects of the ( S) and ( R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of ( R)‐9‐(2‐phosphonomethoxypropyl)‐2,6‐diaminopurine
11. Synthesis of 9‐(2‐phosphonylmethoxyethyl)‐adenine and related compounds
12. Structural studies on bioactive molecules. Part 17. Crystal structure of 9‐(2′‐phosphonomethoxyethyl)adenine (PMEA)
13. Intracellular phosphorylation of broad‐spectrum anti‐DNA virus agent ( S)‐9‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis
14. Biochemical pharmacology of acyclic nucleotide analogues
15. Intracellular metabolism and mechanism of anti‐retrovirus action of 9‐(2‐phosphonylmethoxyethyl)adenine, a potent antihuman immunodeficiency virus compound
16. Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues
17. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus‐encoded enzyme. in vitro
18. Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues
19. Herpes simplex virus‐specified DNA polymerase is the target for the antiviral action of 9–2 (phosphonylmethoxyethyl)adenine
20. Properties of a 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA)‐resistant herpes simplex virus type 1 virus mutant
21. Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV‐1 induced ribonucleotide reductase
22. Inhibition of purine nucleoside phosphorylase by phosphonylmethoxyalkyl analogues of nucleotides
23. The cytostatic effects and mechanisms of action of antiviral acyclic adenine nucleoside analogs in L1210 mouse leukemia cells
24. Cell‐protecting effect against herpes simplex virus‐1 and cellular metabolism of 9‐(2‐phosphonyl‐methoxyethyl)adenine in HeLa S3 cells
25. Cellular uptake of phosphonylmethoxyalkylpurine derivatives
26. Phosphorylation of 9‐(2‐phosphonomethoxyethyl)‐adenine and 9‐(S)‐(3‐hydroxy‐2‐phosphonomethoxy‐propyl) adenine by AMP (dAMP) kinase from L1210 cells
27. 5‐Phosphoribosyl 1‐pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)adenine and 9‐(2‐phosphonylmethoxvethyl)adenine directly to their antivirally active diphosphate derivatives
28. Conversion of acyclic nucleoside phosphonates to their diphosphate derivatives by 5‐phosphoribosyl‐1‐pyrophosphate (PRPP) synthetase
29. Phosphonylmethoxyethyl purine derivatives, a new class of anti‐human immunodeficiency virus agents
30. 9‐(2‐Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replicatio. in vitro and simian immunodeficiency virus infection in rhesus monkeys
31. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes
32. Potent anti‐simian immunodeficiency virus (SIV) activity and pharmacokinetics of 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA) in rhesus monkeys. Proceedings of the International TNO Meeting on Animal Models in AIDS, Maastricht, The Netherlands, 23–26 October 1989
33. Suppression of feline immunodeficiency virus infectio. in vivo by 9‐(2‐phosphonomethoxyethyl)‐adenine
34. In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes
35. Inhibition of visna virus replication by 2′,3′‐dideoxynucleosides and acyclic nucleoside phosphonate analogs
36. Susceptibility of human immunodeficiency virus type 1 replicatio. in vitro to acyclic adenosine analogs and synergy of the analogs with 3′‐azido‐3′deoxythymidine
37. Marke. in vivo antiretrovirus activity of 9‐(2‐phosphonylmethoxyethyl)adenine, a selective anti‐human immunodeficiency virus agent
38. 9‐(2‐Phosphonylmethoxyethyl)‐2,6‐diaminopurine (PMEDAP): a novel agent with anti‐human immunodeficiency virus activit. in vitro and potent anti‐Moloney murine sarcoma virus activity in vivo
39. Antiretroviral efficacy of 9‐(2‐phosphonylmethoxyethyl)adenine and 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diaminopurine in mice infected with Friend leukemia virus [Abstract]. UCLA symposia on Molecular Biology and Cellular Biology—HIV and AIDS: Pathogensis, Therapy and Vaccine Keystone, Colorado, USA, 31 March‐6 April 1990
40. Anti‐retrovirus activity of 9‐(2‐phosphonyl‐methoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered
41. Single‐dose administration of 9‐(2‐phosphonyl‐methoxyethyl)adenine (PMEA) and 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diaminopurine (PMEDAP) in the prophylaxis of retrovirus infectio. in vivo
42. Inhibitory effects of 9‐(2‐ phosphonylmethoxyethyl)adenine and 3′‐azido‐2′,3′‐dideoxythymidine on tumor development in mice inoculated intracerebrally with Moloney murine sarcoma virus
43. 9‐(2‐Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections
44. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS
45. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms
46. Early therapy of feline leukemia virus infection (FeLV‐FAIDS) with 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA)
47. Preexposure prophylaxis with 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA) against simian immunodeficiency virus infection in macaques
48. Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus
49. SM) as a model to evaluate antiviral compounds. Effect of 3′‐azido‐3′‐deoxythymidine, forscarnet and 2′,3′‐dideoxycytidine
50. In vivo antitumor activity of 9‐[(2‐phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues
51. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS‐related complex
52. Immunomodulatory activity of 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA), a potent anti‐HIV nucleoside analogue, o. in vivo murine models
53. Novel acyclic adenosine analogs inhibit Epstein‐Barr virus replication
54. Comparative activities of several nucleoside analogs against duck hepatitis B viru. in vitro
55. Inhibitory effect of 9‐(2‐phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection
56. Comparative efficacy of broad‐spectrum antiviral agents as inhibitors of African swine fever virus replicatio. in vitro
57. Phosphonylmethoxyalkylpurines and ‐pyrimidines as inhibitors of African swine fever virus replicatio. in vitro
58. − herpes simplex virus experimental keratitis
59. − HSV‐1 keratitis in rabbits
60. Effective chemotherapy of equine herpesvirus 1 by phosphonyl‐methoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease
61. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infection. in vivo
62. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis
63. Activity of the anti‐HIV agent 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diaminopurine against cytomegaloviru. in vivo Eur
64. Pharmacokinetics in mice of the anti‐retrovirus agent 9‐(2‐phosphonylmethoxyethyl)‐adenine
65. Acyclic adenine nucleoside phosphonates in plasma determined by high‐performance liquid chromatography with fluorescence detection
66. Transplacental antiretroviral therapy with 9‐(2‐phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice
67. Determination of 9‐[(2‐phosphonylmethoxy)ethyl]adenine in rat urine by high‐performance liquid chromatography with fluorescence detection
68. Efficacy of oral 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diamino‐purine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice
69. Metabolism an. in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phoshonates
70. Synthesis an. in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9‐(2‐phosphonylmethoxy‐ethyl)adenine
71. Drug targeting: anti‐HSV‐1 activity of mannosylated polymer‐bound 9‐(2‐phosphonylmethoxyethyl)‐adenine